Stereotaxis, Inc. (STXS)
Market Cap | 172.00M |
Revenue (ttm) | 25.14M |
Net Income (ttm) | -22.89M |
Shares Out | 84.73M |
EPS (ttm) | -0.27 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 222,782 |
Open | 2.050 |
Previous Close | 2.050 |
Day's Range | 2.010 - 2.060 |
52-Week Range | 1.500 - 3.290 |
Beta | 1.55 |
Analysts | Strong Buy |
Price Target | 4.50 (+121.68%) |
Earnings Date | Nov 11, 2024 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage,... [Read more]
Financial Performance
In 2023, Stereotaxis's revenue was $26.77 million, a decrease of -4.89% compared to the previous year's $28.15 million. Losses were -$22.06 million, 12.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 121.68% from the latest price.
News
Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician...
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial ...
Stereotaxis Reports 2024 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...
Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will p...
Stereotaxis to Present at Upcoming Investor Conferences
ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi...
Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress
ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its tech...
Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval
GenesisX was approved in Europe and is set to be approved in the US late this year. The new robot is a giant leap forward in accessibility. Stereotaxis should get MAGiC approved in Europe in October. ...
Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Adam ...
Stereotaxis Reports 2024 Second Quarter Financial Results
ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been su...
Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024
ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi”...
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the f...
Stereotaxis Receives CE Mark Recertification Under EU's MDR Regulatory Framework
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has rec...
Stereotaxis Makes A Strategic Acquisition Bolstering Its Future
Stereotaxis made a strategic acquisition of catheter company Access Point Technologies, which is expected to contribute $5 million in sales in the first 12 months after the acquisition. Access Point w...
First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology
Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy.
Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa
Stereotaxis presents innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablati
Stereotaxis, Inc. (STXS) Q1 2024 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Offic...
Stereotaxis Reports 2024 First Quarter Financial Results
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...
Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has ent...
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...
Major Regulatory Approvals Coming For Stereotaxis In The Next 10 Months
The Magic catheter human trial was successful. All 20 patients had acute success and there were 0 adverse events. Stereotaxis submitted the Magic catheter to EU and US regulators, with expectations of...
Stereotaxis, Inc. (STXS) Q4 2023 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Frank T...
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulato...
Stereotaxis Reports 2023 Full Year Financial Results
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...